NMDA-based treatment study for major depression
Treatments studied
Part of Mental health clinical trials.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with major depressive disorder (MDD) using DSM-5 criteria
- Your depression symptoms measure high enough on a 17-question Hamilton Depression Scale (score 18 or more)
- You have not taken antidepressant medicines for at least 2 weeks before starting
- You can and agree to participate fully, including signing informed consent and following study rules
- You must not have certain conditions or risks such as bipolar disorder, schizophrenia, or other psychosis
- You should not have recent substance abuse/dependence, serious neurological problems, or moderate-to-severe suicidal risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an NMDA-based treatment for people with major depressive disorder who did not respond to at least one antidepressant. It may help by changing brain signaling linked to depression symptoms.
This study tests a new medication called BMS-986511 for adults with major depressive disorder. It aims to see if the drug can help relieve depression symptoms more effectively than a placebo.
This trial studies how brain signals measured by MRI and EEG may help doctors choose the best treatment for depression. It focuses on people with early-onset, long-lasting or recurring major depression, and tests whether these “brain biomarkers” track with treatment choice and response.
This trial tests a new medication added to your current treatment for chronic depression that hasn't gotten better with at least two antidepressants and 12 therapy sessions. It might help when standard treatments aren't enough.
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.